section name header

General Reference

Factor XI—Nejm 1991;325:153

Pathophys and Cause

Cause:

XI: Genetic, autosomal recessive, incomplete penetrance

IX: Genetic, sex-linked recessive, several types of mutants (Nejm 1970;283:61); or acquired in nephrotics (Ann IM 1970;73:373) and pts w amyloid (binds factor IX) and big spleen, rx w splenectomy (Nejm 1979;301:1050)

Pathophys:Intrinsic system defect (Screening Tests of Clotting Function)

Epidemiology

XI: Common in Ashkenazi Jews, 1/190 people have in Israel; rare in others, <1/million

IX: Prevalence = 1/10 000; 16% of all lifelong bleeding diathesis pts

Signs and Symptoms

Sx:

XI: Rarely spontaneous bleeding; usually only postsurgery

IX: Severe w trauma, surgery; hemarthroses, hematuria

Complications

r/o circulating antibody inhibitors due to SLE, or multiple myeloma

Lab and Xray

Lab: Hem:Clotting w/u (Screening Tests of Clotting Function)

Treatment

Rx:Avoid ASA, indomethacin, phenylbutazone, and other NSAIDs.

Refrigerated blood or plasma since both more stable than factor VIII

of IX deficiency: alphanine; danazol 600 mg qd increases endogenous production (Nejm 1983;308:1393); keep levels 5-15% all the time, >40% for surgery